HD-OPM Archive
Topics › Supplements & vitamins

L-carnitine increased carotid plaque stenosis in a 6-month metabolic syndrome RCT

Louis Nervegna · Jan 27, 2025 · ♥ 14 reactions · 13 comments · original Facebook post
Supplements & vitaminsPlaque, CAC & CT angiographyMeat, eggs & dairy
↻ This is a repost. The main version (highest ranked) is L-carnitine supplements increased carotid plaque stenosis in a 6-month RCT · Jul 18, 2025.
AI summary & key facts

A phase 2 randomized trial in people with metabolic syndrome found L-carnitine supplementation did not change total carotid plaque volume over 6 months but was associated with concerning progression of carotid plaque stenosis versus placebo. TMAO production is the proposed mechanism, though Louis notes carnitine may raise some other causal factor. He views the result as extremely concerning for a widely available supplement.

L-Carnitine supplemention increased carotid plaque stenosis in a recent randomized controlled trial.

This was a phase 2 trial testing carnitine supplementation in patients with metabolic syndrome.

The plaque stenosis increased quickly. It happened in only 6 months in patients taking carnitine, as compared to placebo.

The causal mechanism is thought to be TMAO production.

Carnitine is found naturally in high amounts in red meat.

NOTE: Even if TMAO itself is not causal in heart disease, it may be a marker for something else that is causal. And carnitine may be raising that “something else”, whatever it might be, in addition to raising TMAO. The bottom line is that this randomized controlled trial is extremely concerning. The carnitine supplements appear to be accelerating the progression of atherosclerosis compared to placebo, regardless of the mechanism involved.

Quoted:

“Though total carotid plaque volume did not change in MetS participants taking L-C over 6-months, there was a concerning progression of carotid plaque stenosis. The potential harm of L-C in MetS and its association with pro-atherogenic metabolites raises concerns for its further use as a potential therapy and its widespread availability as a nutritional supplement.”

#carnitineHD #cvdHD #tmaoHD

Paper · Nutr Metab (Lond) · 2022Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndromeBackground L-carnitine (L-C), a ubiquitous nutritional supplement, has been investigated as a potential therapy for cardiovascular disease, but its effects on human atherosclerosis are unknown. Clinical studies suggest improvement of some cardiovascular risk factors, whereas others show increased plasma levels of pro-atherogenic trimethylamine N-oxide. The primary aim was to determine whether L-C therapy led to…nutritionandmetabolism.biomedcentral.com

Research cited

← newer: U-shaped mortality curves for LDL, BMI, A1C and blood pressuolder: Video post with no text →